a thread in polyester (poly(ethylene terephthalate)) with a diameter of 0.85mm and -360mm length, crimped at its proximal end, onto which is mounted a 7mm-wide harpoon, and crimped at its distal end by a triangular-tipped needle, 150mm long, slightly curved at delivery and which can be adjusted during surgery according to a curve suitable for the type of rupture treated;
two perforated lead pellets for tightening;
an UHMW polyethylene disc, with a convex surface offering support that does not excessively compress the skin and a flat surface.
A complete kit required for normal percutaneous tenosynthesis includes two Tenolig®.

AI/ML Overview

The provided document does not contain information about acceptance criteria or a study proving device performance against such criteria. Instead, it is a 510(k) summary for the TENOLIG® surgical suture, primarily focusing on demonstrating substantial equivalence to predicate devices for market clearance.

Here's a breakdown of the requested information based on the provided text, highlighting what is not available:

Table of acceptance criteria and reported device performance:
- Not available. The document states "All results demonstrate that the Tenolig® is safe and effective" but does not define specific acceptance criteria or provide quantitative performance metrics to compare against them.
Sample size used for the test set and the data provenance:
This information is not provided in detail.
- The document mentions "Tensile tests were performed to characterize in tension the strength of the crimping of the braid with the needle and of the braid with the spear." However, it does not specify the sample size for these tests or the data provenance (e.g., country of origin, retrospective/prospective).
Number of experts used to establish the ground truth for the test set and the qualifications of those experts:
- Not applicable. The "performance data" described are mechanical tensile tests and biocompatibility tests, not clinical studies requiring expert ground truth for interpretation of patient data.
Adjudication method for the test set:
- Not applicable. See point 3.
If a multi reader multi case (MRMC) comparative effectiveness study was done, If so, what was the effect size of how much human readers improve with AI vs without AI assistance:
- Not applicable. This document describes a surgical suture, not an AI-powered diagnostic device or a study involving human readers and AI assistance.
If a standalone (i.e. algorithm only without human-in-the-loop performance) was done:
- Not applicable. This is a medical device (surgical suture), not an algorithm.
The type of ground truth used:
- For the mechanical performance tests, the "ground truth" would be the measured physical properties of the suture system (e.g., tensile strength, crimping strength) and compliance with relevant standards.
- For biocompatibility, the "ground truth" refers to the results of biological assays determining the material's safety for body contact, evaluated against the requirements of ISO-10993.
- There is no mention of pathology, outcomes data, or expert consensus in the context of establishing ground truth for performance.
The sample size for the training set:
- Not applicable. This document describes a physical medical device and its performance testing, not a machine learning model so there is no "training set."
How the ground truth for the training set was established:
- Not applicable. See point 8.

Summary

{0}------------------------------------------------

Image /page/0/Picture/0 description: The image is a logo with the letters FH in a bold, sans-serif font. The letters are placed inside of a gear-like shape. Above the gear shape, the word "GROUPE" is written in a smaller, sans-serif font. Below the gear shape, the words "FOURNITURES HOSPITALIERES" are written in a similar font.

6, rue Nobel Z.I. DE KERNÉVEZ 29000 QUIMPER

Tél : 02 98 55 68 95

Fax : 02 98 53 42 13

FRANCE

Image /page/0/Picture/1 description: The image shows the text "FHI industrie" in a bold, sans-serif font. The letters "F," "H," and "I" are capitalized and larger than the rest of the text. A horizontal line underlines the entire word. The dot on the "i" is a solid circle.

510 (K) SUMMARY - TENOLIG®

This summary of 510(k) safety and effectiveness is being submitted in accordance with the requirements of 21 CFR 807.92.

SUBMITTER:

Fournitures Hospitalières Industrie 6 Rue Nobel, Z.I. de Kernevez 29000 QUIMPER, France Phone number: 33.2.98.55.68.95 Fax number: 33.2.98.53.42.13

AUG - 9 2006

payer (2

COMPANY CONTACT:

Christine Quendez Regulatory Affairs Manager Phone number: 33.2.98.55.68.95 Fax number: 33.2.98.53.42.13

DATE PREPARED: Junuary 30th 2006

Image /page/0/Picture/23 description: The image shows a logo with the letters "AFAQ" stacked on top of each other. The letters are in a bold, sans-serif font and are arranged in a square. Below the letters, the text "ISO 9001" is visible. The logo appears to be a certification mark, possibly related to quality management standards.

DEVICE NAME:

Trade Name: TENOLIG® Common name: Nonabsorbable Polyester Surgical Suture Classification name: Non-absorbable poly(ethylene terephthalate) surgical suture 21 C.F.R. Section 888.5000

PREDICATE DEVICES:

Name Manufacturer: 510(K) number:

POLY-TAPES® Xiros Pic. K002172

Name Modified coated VICRYL® Manufacturer: Ethicon Inc. 510(K) number: K022269

DEVICE DESCRIPTION :

Tenolig® consists of:

a thread in polyester (poly(ethylene terephthalate)) with a diameter of 0.85mm and -360mm length, crimped at its proximal end, onto which is mounted a 7mm-wide harpoon, and crimped at its distal end by a triangular-tipped needle, 150mm long, slightly curved at delivery and which can be adjusted during surgery according to a curve suitable for the type of rupture treated;
two perforated lead pellets for tightening; l

। <

{1}------------------------------------------------

K060367 Page 2/2

an UHMW polyethylene disc, with a convex surface offering support that does not excessively compress the skin and a flat surface.
A complete kit required for normal percutaneous tenosynthesis includes two Tenolig®.

INTENDED USE :

Tenolig is indicated for recent ruptures of the Achilles tendon.

TECHNOLOGICAL CHARACTERISTICS AND COMPARISON TO PREDICATE DEVICES :

TENOLIG® is a device for mini-invasive (percutaneous) Achilles tendon suture. To obtain the FDA agreement, we will compare the TENOLIG® with two predicate devices :

The first one is "POLY-TAPES®" from Xiros, which is made with the same material (PET) -
The second one is a braided suture "Vicryl" from Ethicon, which is also used for soft tissue approximation like the Achilles tendon suture.

The mechanical characteristics of TENOLIG® and VICRYL® are compared with a tensile test. The VICRYL® diameter and the kind of suture for this test are determined following the surgical technique of "ACHILLON" from Newdeal (An Integra Lifesciences Company). Both systems have the same indication of use, it means the meeting of the two extremities of Achilles tendon lesion.

PERFORMANCE DATA:

Risk to health have been addressed through the specified materials, processing controls, quality assurance and compliance to the Medical Device Good Manufacturing Practices Regulations.

Performance testing was performed in accordance with the recommendations set up in the FDA Guidance document: « Class II Special Controls Guidance Document: Surgical Sutures; Guidance for Industry and FDA ». Tensile tests were performed to characterize in tension the strength of the crimping of the braid with the needle and of the braid with the spear. All results demonstrate that the Tenolig® is safe and effective.

Biocompatibility testing were conducted according to the NF S 94167 French standard. The results correspond to the requirements of the ISO-10993 standard, which requires to conduct testing in appropriate body contact and duration.

CONCLUSION:

Even if the design of the Tenolig@ and the predicate devices is different, it does not raise new question of safety and effectiveness. The claim of substantial equivalence is based on: On the one hand :

the intended use of the POLY-TAPES® from Xiros and TENOLIG® which are the . same,
the use of the percutaneous tenorraphy to repair Achilles tendon ruptures, -
the post-surgery period which is based on the same principles, -
the material use for the thread.

On the other hand :

On the surgical technique of suture VICRYL® which is similar ー
The technological characteristic differences do not raise new question of safety and effectiveness. Performance testing, biocompatibility testing and clinical data can prove that the Tenolig® is reliable and safe.

The Tenolig® is substantially equivalent to the selected predicate device in terms of intended use, safety, and effectiveness.

{2}------------------------------------------------

Image /page/2/Picture/1 description: The image shows the logo for the Department of Health and Human Services, USA. The logo consists of a circular seal with the text "DEPARTMENT OF HEALTH AND HUMAN SERVICES, USA" arranged around the perimeter. Inside the circle is a stylized graphic of three human profiles facing to the right, stacked on top of each other.

Food and Drug Administration 9200 Corporate Boulevard Rockville MD 20850

AUG - 9 2006

Fournitures Hospitalieres Industrie % Ms. Christine Quendez Regulatory Affairs Manager 6 Rue Nobel, Z.I. de Kernevez 29000 Quimper, France

Re: K060367

Trade/Device Name: TENOLIG® Regulation Number: 21 CFR 878.5000 Regulation Name: Nonabsorbable poly(ethylene terephthalate) surgical suture Regulatory Class: II Product Code: GAT Dated: July 20, 1998 Received: July 24, 1998

Dear Ms. Quendez:

This letter corrects our substantially equivalent letter of July 9, 1998.

We have reviewed your Section 510(k) premarket notification of intent to market the device referenced above and have determined the device is substantially equivalent (for the indications for use stated in the enclosure) to legally marketed predicate devices marketed in interstate commerce prior to May 28, 1976, the enactment date of the Medical Device Amendments or to devices that have been reclassified in accordance with the provisions of the Federal Food, Drug, and Cosmetic Act (Act) that do not require approval of a premarket approval (PMA). You may, therefore, market the device, subject to the general controls provisions of the Act. The general controls provisions of the Act include requirements for annual registration, listing of devices, good manufacturing practice, labeling, and prohibitions against misbranding and adulteration.

If your device is classified (see above) into either class II (Special Controls) or class III (PMA), it may be subject to additional controls. Existing major regulations affecting your device can be found in the Code of Federal Regulations, Title 21, Parts 800 to 898. In addition, FDA may publish further announcements concerning your device in the Federal Register.

Please be advised that FDA's issuance of a substantial equivalence determination does not mean that FDA has made a determination that your device complies with other requirements of the Act or any Federal statutes and regulations administered by other Federal agencies. You must comply with all the Act's requirements, including, but not limited to: registration and listing (21 CFR Part 807); labeling (21 CFR Part 801); good manufacturing practice requirements as set forth in the quality systems (QS) regulation (21 CFR Part 820); and if applicable, the electronic product radiation control provisions (sections 531-542 of the Act); 21 CFR 1000-1050.

{3}------------------------------------------------

Page 2 – Ms. Christine Quendez

This letter will allow you to continue marketing your device as described in your Section 510(k) premarket notification. The FDA finding of substantial equivalence of your device to a legally marketed predicate device results in a classification for your device and thus, permits your device to proceed to the market.

If you desire specific advice for your device on our labeling regulation (21xCFR Part 801), please contact the Office of Compliance at (240) 276-0115. Also, please note the regulation entitled, "Misbranding by reference to premarket notification" (21CFR Part 807.97). You may obtain other general information on your responsibilities under the Act from the Division of Small Manufacturers, International and Consumer Assistance at its toll-free number (800) 638-2041 or (240) 276-3150 or at its Internet address http://www.fda.gov/cdrh/dsma/dsmamain.html

Sincerely yours,

Hubert Leimer no

Mark N. Melkerson Director Division of General, Restorative and Neurological Devices Office of Device Evaluation Center for Devices and Radiological Health

Enclosure

{4}------------------------------------------------

Fournitures Hospitalieres Industrie

TENOLIG® Traditional 510(k) Premarket Notification

Indications for Use

510(k) Number (if known):

Prescription Use

(Part 21 CFR 801 Subpart D)

K060367

Device Name:

TENOLIG®

Indications for Use:

TENOLIG® is indicated for surgical repair of Achilles tendon ruptures by percutaneous approach

Helene Leiner

Division Sign-Division of General, Restorative, and Neurological Devices Over the counter Use

(PLEASE DO NOT WRITE BELOW THIS LINE-CONTINUE ON ANOTHER PAGE OF NEEDED)

AND/OR

Concurrence of CDRH, Office of Device Evaluation (ODE)

of of of Page _________________________________________________________________________________________________________________________________________________________________________

Regulation Number and Section

§ 878.5000 Nonabsorbable poly(ethylene terephthalate) surgical suture.

(a)
Identification. Nonabsorbable poly(ethylene terephthalate) surgical suture is a multifilament, nonabsorbable, sterile, flexible thread prepared from fibers of high molecular weight, long-chain, linear polyesters having recurrent aromatic rings as an integral component and is indicated for use in soft tissue approximation. The poly(ethylene terephthalate) surgical suture meets U.S.P. requirements as described in the U.S.P. Monograph for Nonabsorbable Surgical Sutures; it may be provided uncoated or coated; and it may be undyed or dyed with an appropriate FDA listed color additive. Also, the suture may be provided with or without a standard needle attached.(b)
Classification. Class II (special controls). The special control for this device is FDA's “Class II Special Controls Guidance Document: Surgical Sutures; Guidance for Industry and FDA.” See § 878.1(e) for the availability of this guidance document.